Cargando…

Gut microbiota: A new therapeutic target for diabetic cardiomyopathy

Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and au...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Suxin, Cai, Zhengyao, Luan, Xingzhao, Wang, Haibo, Zhong, Yi, Deng, Li, Feng, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461091/
https://www.ncbi.nlm.nih.gov/pubmed/36091756
http://dx.doi.org/10.3389/fphar.2022.963672
_version_ 1784786901704638464
author Yuan, Suxin
Cai, Zhengyao
Luan, Xingzhao
Wang, Haibo
Zhong, Yi
Deng, Li
Feng, Jian
author_facet Yuan, Suxin
Cai, Zhengyao
Luan, Xingzhao
Wang, Haibo
Zhong, Yi
Deng, Li
Feng, Jian
author_sort Yuan, Suxin
collection PubMed
description Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Some studies have shown that gut microbiota plays an important role in cardiovascular diseases. Gut microbiota and its metabolites can affect the development of diabetic cardiomyopathy by regulating oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Here, the mechanisms of gut microbiota and its metabolites resulting in diabetic cardiomyopathy are reviewed. Gut microbiota may be a new therapeutic target for diabetic cardiomyopathy.
format Online
Article
Text
id pubmed-9461091
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94610912022-09-10 Gut microbiota: A new therapeutic target for diabetic cardiomyopathy Yuan, Suxin Cai, Zhengyao Luan, Xingzhao Wang, Haibo Zhong, Yi Deng, Li Feng, Jian Front Pharmacol Pharmacology Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Some studies have shown that gut microbiota plays an important role in cardiovascular diseases. Gut microbiota and its metabolites can affect the development of diabetic cardiomyopathy by regulating oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Here, the mechanisms of gut microbiota and its metabolites resulting in diabetic cardiomyopathy are reviewed. Gut microbiota may be a new therapeutic target for diabetic cardiomyopathy. Frontiers Media S.A. 2022-08-26 /pmc/articles/PMC9461091/ /pubmed/36091756 http://dx.doi.org/10.3389/fphar.2022.963672 Text en Copyright © 2022 Yuan, Cai, Luan, Wang, Zhong, Deng and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yuan, Suxin
Cai, Zhengyao
Luan, Xingzhao
Wang, Haibo
Zhong, Yi
Deng, Li
Feng, Jian
Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title_full Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title_fullStr Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title_full_unstemmed Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title_short Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
title_sort gut microbiota: a new therapeutic target for diabetic cardiomyopathy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461091/
https://www.ncbi.nlm.nih.gov/pubmed/36091756
http://dx.doi.org/10.3389/fphar.2022.963672
work_keys_str_mv AT yuansuxin gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT caizhengyao gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT luanxingzhao gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT wanghaibo gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT zhongyi gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT dengli gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy
AT fengjian gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy